TargetA and TargetB exhibit only 55.65% homology, presenting a substantial barrier for the generation of high-affinity cross-reactive antibodies. Standard discovery workflows often lead to unbalanced potency or loss of binding for the less conserved target.

AlfaBodY Solution:
● Precision Screening: Screened 222 candidate antibodies across four intensive rounds of selection.
● Synchronized Optimization: Boosting anti-TargetA affinity while simultaneously maintaining anti-TargetB affinity each round.
● In Vitro Potency: Cellular functional assays demonstrated exceeding the primary reference benchmark.
● In Vivo Proof-of-Concept: Animal models confirmed statistically significant superior efficacy compared to the benchmark, validating the therapeutic potential of the dual-blockade mechanism.